Oncolytics Biotech (TSE:ONC) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Oncolytics Biotech is set to showcase promising results of their immunotherapy drug, pelareorep, in treating hard-to-treat gastrointestinal cancers at the upcoming ASCO GI Symposium. The data highlights pelareorep’s ability to enhance the effectiveness of existing cancer treatments, potentially improving patient outcomes in pancreatic and anal cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
